Imunon (Imunon) 6-1 Month Momentum % : -12.00% (As of Apr. 25, 2024)

View and export this data going back to 1999. Start your Free Trial

What is Imunon 6-1 Month Momentum %?

6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2024-04-25), Imunon's 6-1 Month Momentum % is -12.00%.

The industry rank for Imunon's 6-1 Month Momentum % or its related term are showing as below:

IMNN's 6-1 Month Momentum % is ranked worse than
65.66% of 1517 companies
in the Biotechnology industry
Industry Median: 3.45 vs IMNN: -12.00

Competitive Comparison of Imunon's 6-1 Month Momentum %

For the Biotechnology subindustry, Imunon's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Imunon's 6-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Imunon's 6-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Imunon's 6-1 Month Momentum % falls into.

Imunon (NAS:IMNN) 6-1 Month Momentum % Calculation

6-1 Month Momentum % is calculated as following:

6-1 Month Momentum %

( Price 1-month ago

Price 6-month ago

- 1 )

100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Imunon (NAS:IMNN) 6-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Imunon 6-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Imunon's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.

Imunon (Imunon) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Imunon Inc (NAS:IMNN) » Definitions » 6-1 Month Momentum %

Comparable Companies

Traded in Other Exchanges

CBO:Germany

Address

997 Lenox Drive, Suite 100, Lawrenceville, NJ, USA, 08648

Website

https://www.imunon.com

Imunon Inc is developing new medicines that harness the building blocks of life to work in harmony with the body's immune system. It is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases.

Executives

James E Dentzer	director	C/O AMICUS THERAPEUTICS, INC., 6 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Le Goff Corinne	director, officer: President and CEO	200 TECHNOLOGY SQUARE, SUITE 300, CAMBRIDGE MA 02139
Michael H Tardugno	officer: Chief Executive Offier	10220-L OLD COLUMBIA ROAD, COLUMBIA MD 21046-2364
Frederick J. Fritz	director	C/O CELSION CORPORATION, 10220-L OLD COLUMBIA ROAD, COLUMBIA MD 21046
Kardaras Constantine John	officer: Chief Accounting Officer	C/O CELSION CORPORATION, 997 LENOX DRIVE, SUITE100, LAWRENCEVILLE NJ 08648
Christine A Pellizzari	director	10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Stacy Lindborg	director	C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF AMERICAS, 28TH FLR., NEW YORK NY 10019
Donald P Braun	director	C/O CELSION CORPORATION, 997 LENOX DRIVE, SUITE 100, LAWRENCEVILLE NJ 08648
Alberto R Martinez	director	C/O CELSION CORPORATION, 997 LENOX DRIVE, SUITE 100, LAWRENCEVILLE NJ 08648
Jeffrey Wayne Church	officer: Chief Financial Officer
Robert W Hooper	director	C/O CELSION CORPORATION, 10220-L OLD COLUMBIA ROAD, COLUMBIA MD 21046
Andreas Voss	director	C/O CELSION CORPORATION, 997 LENOX DRIVE, SUITE 100, LAWRENCEVILLE NJ 08648
Egwu, Inc. Fka Egen, Inc.	10 percent owner	601 GENOME WAY, SUITE 3400, HUNTSVILLE AL 35806
Khursheed Anwer	officer: Chief Scientific Officer	C/O CELSION CORPORATION, 997 LENOX DRVIE, SUITE 100, LAWRENCEVILLE NJ 08648
Gregory L Weaver	director	185 BERRY STREET, SUITE 6504, SAN FRANCISCO CA 94107